Arcutis Biotherapeutics, Inc. (ARQT) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ARQT Revenue Growth
Revenue Breakdown (FY 2023)
ARQT's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ARQT Revenue Analysis (2017–2025)
As of May 6, 2026, Arcutis Biotherapeutics, Inc. (ARQT) generated trailing twelve-month (TTM) revenue of $415.6 million, reflecting explosive growth of +60.1% year-over-year. The most recent quarter (Q1 2026) recorded $105.4 million in revenue, down 18.6% sequentially.
Looking at the longer-term picture, ARQT's historical revenue data shows a 3-year CAGR of +367.3%. The company achieved its highest annual revenue of $376.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ARQT's business is primarily driven by Other Revenue (51%), and Product (49%). With over half of revenue concentrated in Other Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including DERM (-27.4% YoY), NVCR (+8.5% YoY), and PRGO (-3.6% YoY), ARQT has outperformed the peer group in terms of revenue growth. Compare ARQT vs DERM →
ARQT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARQTCurrent | $416M | +60.1% | - | -3.3% | |
 DERM | $56M | -27.4% | +10.0% | -24.4% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 DAWN | $158M | +20.6% | - | -80.8% |
ARQT Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $376.1M | +91.3% | $339.4M | 90.2% | $-12,227,000 | -3.3% |
| 2024 | $196.5M | +229.7% | $177.4M | 90.3% | $-128,397,000 | -65.3% |
| 2023 | $59.6M | +1517.1% | $54.6M | 91.6% | $-241,101,000 | -404.5% |
| 2022 | $3.7M | - | $2.9M | 79.5% | $-301,627,000 | -8183.0% |
| 2021 | $0 | - | $-763,000 | - | $-206,529,000 | - |
| 2020 | $0 | - | $-455,000 | - | $-136,645,000 | - |
| 2019 | $0 | - | $-195,000 | - | $-43,132,000 | - |
| 2018 | $0 | - | $0 | - | $-19,735,000 | - |
| 2017 | $0 | - | $0 | - | $-4,106,000 | - |
See ARQT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARQT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARQT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
Is ARQT's revenue growth accelerating or slowing?
ARQT revenue is accelerating at +60.1% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $416M. Growth momentum has increased versus prior periods.
What is ARQT's long-term revenue growth rate?
Arcutis Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +60.1% is above this long-term average.
How is ARQT's revenue distributed by segment?
ARQT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.